Veracyte detailed plans to launch TrueMRD for muscle‑invasive bladder cancer and expand its whole‑transcriptome sequencing capabilities while targeting reimbursement pathways and guideline inclusion. The company intends a staged rollout with upfront and surveillance billing codes and aims to use clinical utility and registrational data to support uptake. Complementing commercial moves, the BloodPAC consortium published harmonized analytical validation protocols for tumor‑informed ctDNA MRD assays, offering standardized approaches for limit of detection, precision, and specimen stability. Together the commercial launch and consortium guidance signal accelerating clinical adoption and regulatory scrutiny of MRD tests across oncology.